Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

FDA Approves First Anti-PDL1 Cancer Immunotherapy for Metastatic Lung Cancer

XTALKS VITALS NEWS

Lung Cancer

The anti-PDL1 cancer immunotherapy is indicated for patients with tumors containing EGFR or ALK gene abnormities, and those who have experienced disease progression following platinum-containing chemotherapy.

Tweetables from this article:

Tweet: Patients taking Tecentriq lived 4.2 months longer than those treated with the standard docetaxel #chemotherapy http://ctt.ec/_Xe84+ Patients taking Tecentriq lived 4.2 months longer than those treated with the standard docetaxel chemotherapy.

Share this!

October 20, 2016 | by Sarah Hand, M.Sc.

Roche’s biotechnology division, Genentech, has just received US Food and Drug Administration (FDA) approval for their non-small cell lung cancer drug, Tecentriq (atezolizumab). The anti-PDL1 cancer immunotherapy is indicated for patients with tumors containing EGFR or ALK gene abnormities, and those who have experienced disease progression following platinum-containing chemotherapy.

The FDA approval was based on data collected during a Phase II clinical trial – dubbed POPLAR – along with a Phase II study, known as OAK. In the OAK clinical trial, patients taking Tecentriq lived 4.2 months longer than those treated with the standard docetaxel chemotherapy.

“Tecentriq is a new option to help people with this type of previously treated metastatic lung cancer, regardless of PD-L1 expression, live longer than chemotherapy,” said Dr. Sandra Horning, chief medical officer and head of global product development for Genentech. “Tecentriq is the first and only approved cancer immunotherapy designed to target the PD-L1 protein, which may play an important role in the way the medicine works.”



The OAK clinical trial enrolled patients with both squamous and non-squamous types of lung cancer, and did not discriminate based on PD-L1 status. In all, over 15 clinical trials have been conducted to assess Tecentriq, including seven Phase III studies using the immunotherapy as a possible first-line treatment for lung cancer.

Tecentriq is a monoclonal antibody which binds to the PD-L1 protein expressed on certain tumor cells. As an immunotherapy, the drug is designed to stimulate the activation of T cells to detect and destroy cancer cells. The Phase III OAK clinical trial is a global, multicenter, open-label, randomized, controlled study, which compared the safety and efficacy of Tecentriq compared to docetaxel, in 1,225 patients with NSCLC.

“Over the past 15 years, survival rates for advanced lung cancer have been consistently improving,” said Bonnie J. Addario, a lung cancer survivor and founder of the Bonnie J. Addario Lung Cancer Foundation (ALCF). “The approval of Tecentriq is another important step for patients by increasing the number of medicines available to people living with lung cancer.”

Over 224,000 Americans will be diagnosed with lung cancer this year, according to statistics from the American Cancer Society. NSCLC accounts for almost 85 percent of lung cancer cases, with many diagnoses being made once the disease has entered the most advanced stages.


Keywords: Lung Cancer, Immunotherapy, FDA


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Exclusion Criteria for Clinical Trials Poses Major Barrier to Patient Enrollment

August 17, 2017 - UT Southwestern researchers say that clinical investigators continue to increase the number of exclusion criteria, preventing more patients from participating in clinical trials.

Featured In: Clinical Trials News


Targeting Cellular Nitrogen Metabolism Could Offer a New Treatment for Pancreatic Cancer

August 17, 2017 - An enzyme involved in regulating the amount of nitrogen in the cell could be a new drug target for pancreatic cancer, according to researchers from Boston Children's Hospital and the Broad Institute of MIT and Harvard.

Featured In: Life Science News


Regeneron’s Drug for Respiratory Syncytial Virus Fails in Phase III Clinical Trial

August 16, 2017 - Biotechnology company Regeneron has announced it will not continue development of its antibody drug, suptavumab, after a failure in a Phase III clinical trial.

Featured In: Clinical Trials News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

One Patient’s Perspective on Clinical Trials

REGISTER FOR THESE WEBINARS

Planning and Conducting Trials of the Latest Immunotherapies


ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation


Medical Devices: Reviewing Regulatory Changes in the US and EU


Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.